Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers 

Slides:



Advertisements
Similar presentations
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Erik De Clercq International Journal of Antimicrobial Agents Volume 33,
Advertisements

The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Pascal Rischmann  European Urology Supplements 
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer  Olav Erich Yri, Trine Bjoro, Sophie D.
John P. Mulhall, Francesco Montorsi  European Urology 
Martin C. Michel  European Urology Supplements 
Bladder Cancer: A Major Public Health Issue
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
A Novel Treatment of Premature Ejaculation
Counselling the Prostate Cancer Patient
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
An Update of Current Practice in Hypospadias Surgery
Richard C. Harkaway  European Urology Supplements 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
The Importance of Testosterone Control in Prostate Cancer
Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL)  Martin C. Michel,
Optimal Testosterone Control and Eligard®
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Neal Shore  European Urology Supplements 
Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH
Nicholas D. James, Jim W. Growcott  European Urology Supplements 
Sergio Bracarda  European Urology Supplements 
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Christian Stief  European Urology Supplements 
European Urology is “Your” Journal
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Pharmacokinetics and safety of multiple oral doses of sustained-release 4- aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord.
Preclinical Profile of Zoledronic Acid in Prostate Cancer Models
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Who Forms Stones and Why?
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
Retrocaval Ureter—Magnetic Resonance Appearances
Richard Berges  European Urology Supplements 
The Burden of Stress Urinary Incontinence
Profile of Silodosin European Urology Supplements
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
M.B. Kerrn, N. Frimodt-Møller, F. Espersen 
Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin  G. Drusano  Clinical Microbiology and Infection 
Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation  Martin.
The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study  Bob Djavan,
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Testim® Gel: Review of Clinical Data
Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects  Martin C. Michel, Cees Korstanje, Walter.
Kpop: A Python package for population genetics analysis
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Antoinette A. Westen, Titia Sijen 
Bertrand Tombal, Richard Berges
Joaquim Bellmunt  European Urology Supplements 
Pitavastatin and HDL: Effects on plasma levels and function(s)
Hormone Therapy: Improving Therapy Decisions and Monitoring
The Impact of Premature Ejaculation on Partners and Relationships
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Kennedy J.M. , van Rij A.M.   British Journal of Anaesthesia 
Providing Constant Analgesia with OROS® Hydromorphone
Diagnosis and Management of Cryptorchidism
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Jan Roigas  European Urology Supplements 
Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL)  Martin C. Michel,
Volume 4, Issue 1, Pages 2-3 (February 2006)
Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?  B. Tombal  European Urology.
Presentation transcript:

The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS®)  Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers  European Urology Supplements  Volume 4, Issue 2, Pages 15-24 (February 2005) DOI: 10.1016/j.eursup.2004.11.002 Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 1 Schematic representations of different MR technologies: (A) multi-unit membrane-coated pellets, (B) Oros®, (C) GeoMatrix®. European Urology Supplements 2005 4, 15-24DOI: (10.1016/j.eursup.2004.11.002) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 2 Schematic representation of OCAS® hydration and drug release in small intestine and colon compared with conventional matrix hydration. European Urology Supplements 2005 4, 15-24DOI: (10.1016/j.eursup.2004.11.002) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 3 Tamsulosin OCAS 0.4mg tablet dissolution data (n=6). Dissolution was carried out for the S2, S3 and S4 formulations using the Ph Eur paddle method (200rpm) using water at 37°C as the dissolution medium. Data are expressed as mean±standard deviation. European Urology Supplements 2005 4, 15-24DOI: (10.1016/j.eursup.2004.11.002) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 4 Mean trough plasma concentrations during multiple dosing of one (0.4mg), two (0.8mg) or three (1.2mg) tablets of tamsulosin OCAS S3 0.4mg in the fasted state and one tablet of tamsulosin OCAS S3 0.4mg in the fed state. The curves represent the average values of 24 subjects; the error bars represent the standard deviation. European Urology Supplements 2005 4, 15-24DOI: (10.1016/j.eursup.2004.11.002) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 5 Mean plasma concentration vs. time profiles of multiple dosing of tamsulosin OCAS S3 0.4mg in the fasted and the fed state. The curves represent the average values of 24 subjects. A quantitative analysis of the data is presented in Table 2. European Urology Supplements 2005 4, 15-24DOI: (10.1016/j.eursup.2004.11.002) Copyright © 2004 Elsevier B.V. Terms and Conditions